Troy A. Ignelzi - Jan 17, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Financial Officer
Signature
/s/ Troy Ignelzi
Stock symbol
KRTX
Transactions as of
Jan 17, 2023
Transactions value $
-$195,224
Form type
4
Date filed
1/19/2023, 03:45 PM
Previous filing
Dec 19, 2022
Next filing
Feb 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $7.52K +817 +3.74% $9.20* 22.7K Jan 17, 2023 Direct
transaction KRTX Common Stock Sale -$165K -817 -3.61% $201.41 21.8K Jan 17, 2023 Direct F1
transaction KRTX Common Stock Options Exercise $1.84K +200 +0.92% $9.20* 22K Jan 18, 2023 Direct
transaction KRTX Common Stock Sale -$40K -200 -0.91% $200.14 21.8K Jan 18, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -817 -0.74% $0.00 110K Jan 17, 2023 Common Stock 817 $9.20 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -200 -0.18% $0.00 110K Jan 18, 2023 Common Stock 200 $9.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.